About this trial
The patients will be randomly assigned to one of the two groups according to the treatment method: group I (masseter group) and group II (masseter \&sternocleidomastoid group) where each patient will be injected 0.5ml in each trigger point (TrPs) of magnesium sulphate according to the treatment group by the same operator. The treatment method for TrPs will be the primary predictor variable. Patients will be examined at the following intervals: during diagnosis, 1-month, 3-months, and 6-months post-injection. The participated patients will be assessed using pain score measured on a 10-point visual analogue scale (VAS), the 0 indicating no pain and 10 indicating the worst pain ever
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
definite diagnosis of myofascial pain
presence of one or more unilateral or bilateral trigger points in the masseter muscle and sternocleidomastoid muscle;
no history of any invasive procedures of the related masseter muscle.
Disqualifiers
any painful conditions (other than myofascial trigger points) affecting the orofacial region
any systemic diseases that could masticatory function (e.g., rheumatoid arthritis and epilepsy);
pregnancy and lactation
Trial design
Parallel
Treatments tested in this trial
masseter muscle
Drugmasseter muscle trigger points injection by magnesium sulphate
masseter and sternocleidomastoid muscle
Drugmasseter and sternocleidomastoid muscle trigger points injection by magnesium sulphate
Treatment groups
Trial outcomes
Primary outcomes
muscle pain
by visual analogue scal
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: